Thomas Andrew Crockett - Feb 1, 2024 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Stock symbol
KALV
Transactions as of
Feb 1, 2024
Transactions value $
-$162,198
Form type
4
Date filed
2/5/2024, 05:55 PM
Previous filing
Dec 28, 2023
Next filing
Feb 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALV Common Stock Sale -$150K -9.3K -7.29% $16.18 118K Feb 1, 2024 Direct F1, F2
transaction KALV Common Stock Sale -$11.8K -700 -0.59% $16.81 118K Feb 1, 2024 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 31, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.77 to $16.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.77 to $16.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.